Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / Meltzer 3-marker panel for Esophageal Adenocarcinoma

Meltzer 3-marker panel for Esophageal Adenocarcinoma

Basics

Attributes

QA State: Under Review
Short Name:
HGNC Name:

Using real-time quantitative methylation-specific PCR, ten genes (HPP1, RUNX3, RIZ1, CRBP1, 3-OST-2, APC, TIMP3, p16, MGMT and p14) were screened for promoter hypermethylation in 77 esophageal adenocarcinoma, 93 Barrett's Esophagus, and 64 normal esophagus specimens. p16, RUNX3 and HPP1 displayed increasing methylation frequencies in Barrett's Esophagus vs. esophageal adenocarcinoma samples, with the increases in methylation occurring early, at the interface between Barrett's Esophagus and low-grade dysplasia. Further study has shown that hypermethylation of p16 and HPP1 are independently associated with an increased risk of progression. In combined analyses, risk was detectable up to, but not earlier than, two years prededing neoplastic progression. Hypermethylation of p16, RUNX3 and HPP1 in Barrett's Esophagus or low-grade dysplasia may represent independent risk factors for the progression of Barrett's Esophagus to high-grade dysplasia or esophageal adenocarcinoma.

Panel Details

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.